VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO, Cameron Reynolds updating the company's shareholders.

In the letter, Mr. Reynolds outlines several significant accomplishments to date and highlights the fact that the company believes that it is close to achieving a key clinical milestone with the completion of a 680-subject trial for the Nu.Q^TM Frontline Asymptomatic Colorectal Cancer Screening Test. Volition expects to report the results from this study in early February.

"We believe that this will be our most important data release to date, given the fact that this product is for the large frontline screening market, and that it will show the accuracy of our test in a sizable cohort with a large number of assays tested" stated Mr. Reynolds.

"The study, conducted in collaboration with the Hvidovre Hospital of the University of Copenhagen, included 680 asymptomatic colorectal cancer screening subjects (including 100 cancers), and tested up to 30 assays including the largest number of Nu.Q markers tested to date, and some established orthogonal markers. From this study, a small number of markers will be taken into Volition's very large European trials this year and the company expects that this will give it a strong indication for one or more U.S. products.

This study has given us the confidence to start the next stage with a study of some 4,300 subjects, the results of which we hope to complete by March 31, 2018. We then plan to complete a large blinded 10,000+ subject study in the second quarter of 2018 to ensure that we have the data in multiple trials to back up our product claims this year. We also expect to get a CE Mark in parallel so that the Nu.Q Frontline Asymptomatic Colorectal Cancer Screening Test will be registered for sale in the 28 European Union member states by September 30, 2018. We believe that this represents a very large commercial opportunity for Volition with a total addressable market of approximately 150 million people of screen relevant age." continued Mr. Reynolds.

"We are also delighted to announce the completion of the Triage Pathway Design Study in Denmark with the report anticipated by the end of January.

Volition kicks off 2018 hosting a range of meetings at Healthcare week in San Francisco, California from January 8 through January 12, 2018. Should you wish to meet with the management team please contact Louise Day, 

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.